Clinical Trial Update: Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression [Phase 2]

View source ↗

Summary

Phase 2 proof-of-concept trial evaluating augmentation of antidepressant therapy with CERC-501 in treatment-resistant depression was terminated; results were po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Treatment-resistant Depression

Drugs mentioned

• CERC-501

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Treatment Resistant Depression | Phase 2 | Status: TERMINATED | Results posted: 2017-07-02